Nona Biosciences — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Nona Biosciences is a private, platform-focused biotech company founded in 2021 that leverages its proprietary Harbour Mice® transgenic platform to discover fully human antibodies for therapeutic development. The company operates primarily as a service and partnership-driven CRO, offering end-to-end solutions from idea to IND, with a strong track record of over 300 projects and 19+ INDs/clinical-stage programs for its 100+ partners. Its technology portfolio is enhanced by an AI-powered platform, Hu-mAtrIx™, and is designed to accelerate the creation of complex modalities like bispecifics and cell therapies. Nona is positioned as an enabling partner in the rapidly growing field of biologics and next-generation antibody therapeutics.

Antibodies

Technology Platform

Proprietary Harbour Mice® transgenic platform for generating fully human conventional (H2L2) and heavy-chain-only (HCAb) antibodies, augmented by AI-powered discovery (Hu-mAtrIx™) and specialized toolkits for bispecifics (HBICE®), CAR-T (NonaCarFx™), and functional screening (NonaHCAbFx™).

Opportunities

The company is positioned at the center of high-growth trends in bispecific antibodies, ADCs, and cell therapies, with a platform that provides the essential building blocks for these modalities.

Its partnership-driven, 'Idea to IND' service model allows it to capture value from the expanding biologics outsourcing market without the capital intensity of drug development.

Risk Factors

Key risks include intense competition in the antibody discovery CRO and platform licensing space, dependence on the biotech funding environment for partnership flow, and the long-term risk of technological disruption to antibody-based therapeutics.

Its business is also heavily reliant on defending its core intellectual property.

Competitive Landscape

Nona competes with other transgenic antibody platform companies (e.g., Ligand's OmniAb, Ablexis/AlivaMab), large CROs with biologics capabilities (e.g., Charles River, Labcorp), and specialized antibody discovery firms (e.g., AbCellera, Distributed Bio). Its differentiation lies in the combination of fully human HCAb generation, an integrated service suite, and AI-enhanced prioritization.

More companies in Biologics / Biosimilars →More companies in United States →